Navigation Links
Study Confirms Soy Isoflavones Reduce Menopausal Hot Flashes
Date:4/4/2012

DECATUR, Ill., April 4, 2012 /PRNewswire/ -- Archer Daniels Midland Company (NYSE: ADM) is pleased to share the results of a new meta-analysis on the effects of soy isoflavones in the alleviation of menopausal hot flashes. The analysis, which was published March 19 by Menopause: The Journal of The North American Menopause Society, found clear and consistent evidence that soy isoflavone supplements, like NovaSoy brand soy isoflavones, are significantly more effective than placebo in reducing the frequency and severity of hot flashes.

"The key finding in this study is that when you limit the analysis to isoflavone supplements derived from soy or those with profiles identical to soy, there is a very consistent effect on hot flash relief," said Mindy S. Kurzer, Ph.D, professor of nutrition at the University of Minnesota, hormone expert and contributing author to the study. "Almost all studies in the meta-analysis show a consistent reduction in hot flash frequency and severity."

The meta-analysis – which is the largest and most comprehensive conducted to date – revealed that ingestion of soy isoflavones for six weeks to 12 months significantly reduced the frequency of hot flashes by more than 20 percent compared with placebo. Soy isoflavones also significantly reduced hot flash severity by more than 26 percent compared with placebo. The analysis found that the decrease in hot flash frequency in longer duration trials (more than 12 weeks) was approximately threefold greater than the decrease in shorter-duration trials.

"For women who are bothered by hot flashes, any reduction in frequency or severity may be welcome – especially if it can be achieved without side effects," said Melissa K. Melby, Ph.D (University of Delaware), hot flash expert and contributing author to the study. "Soy isoflavones appear to be a good first approach to
'/>"/>

SOURCE Archer Daniels Midland Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... 16, 2011 Get content from European Parliament ... The European Parliament is expected to pass ... medicines from entering the legal distribution chain in ... reached patients in the last years. The legislation ...
... SUNNYVALE, Calif., Feb. 16, 2011 ... today announced it will showcase its network scanning solutions ... hospitals and patients at the Annual HIMSS Conference & ... The adoption of network scanners has gained tremendous ...
Cached Medicine Technology:Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 2Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... techniques such as Dynamic Neuromuscular Stabilization, Extracorporeal Shock ... analysis. After moving to upgraded facilities in 2011, ... clinic. Now, owner Dr. Lev Kalika has launched ... injury prevention lab in the country. , The ...
(Date:11/28/2014)... The holiday season is fast approaching. As ... new collection of fashionable party dresses. What’s more, the company ... these brand new outfits; the special offer is valid until ... online supplier and it has received a lot of requests ... specially designed to flatter various body shapes; they are available ...
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Orlando, FL (PRWEB) November 28, 2014 ... management solutions, announced its Release v5.1 which provides ... and enhanced workflow options. , “As we ... we continue to provide more functionality and improved ... states Robert Gambotz, CEO for Novatus. “With the ...
(Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... treatment to her practice called Ultrashape that is designed to ... inches in just six weeks. Ultrashape has been praised by ... in results when compared to other types of external fat ... it,” said Dr. Walder. , According to Dr. Walder, ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... called NFATc1 tends to cause massive bone accumulation that ... investigator Gerald Crabtree and HHMI predoctoral fellow Monte Winslow ... formed and being broken down throughout life. Cells called ... it. ,‘Ideally, they are perfectly balanced,’ ...
... useful for the young doctors, to overcome the fatigue, who ... a little of sleep will lead to a substantial improvement ... doctors ability to care for their patients. ,In the ... researchers from the University of Chicago report that although average ...
... under-diagnosed till now was found to be more prevalent ... Explosive Disorder or Rage disorder is characterized by recurrent ... if left untreated may also lead to other mental ... attacks are out of proportion to the social stressors ...
... has revealed that men reaching fatherhood late in life may ... the genetic damage that increases with age//. ,US ... non-smoking men aged 22 to 80 and found a prevalence ... can be manifested as symptoms such as infertility, difficulty in ...
... The House of Representatives have passed a controversial bill ... would effectively take away //the power from local & ... foods and beverages that are likely to cause cancer, ... substances like mercury, like those required in California and ...
... for people with mild asthma, shallow breathing through the ... people to use a reliever inhaler very rarely//. ... are the most commonly used alternative for inhalers. A ... used by many people with asthma. ,Since ...
Cached Medicine News:Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 2Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3Health News:Fathering Best Done In Early Years 2Health News:Association Asks People To Tell Their Senator To Vote against The "National Food Uniformity Act" 2
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... exists as unbound or free testosterone. The ... with high affinity [1], while the remainder ... albumin-bound and free fractions may be biologically ... Measurement of the free or unbound fraction ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
Medicine Products: